STATE OF MINNESOTA FORTY-EIGHTH MEETING
HOUSE OF REPRESENTATIVES NINETY-FIRST SESSION
HEALTH AND HUMAN SERVICES FINANCE DIVISION
MINUTES
Representative Liebling, Chair of the Division, called the meeting to order at 12:49 P.M. on February 27, 2020 in Room 200 of the State Office Building.
The Committee Legislative Assistant noted the roll.
Members present:
LIEBLING, Tina, Chair
SCHOMACKER, Joe, Lead Republican
ACOMB, Patty
BIERMAN, Robert
CANTRELL, Hunter
FRANSON, Mary
GRUENHAGEN, Glenn
HALEY, Barb
HALVERSON, Laurie
HAMILTON, Rod
JORDAN, Sydney
KIEL, Debra
KUNESH-PODEIN, Mary
MORAN, Rena
MUNSON, Jeremy
NOOR, Mohamud
OLSON, Liz
SCHULTZ, Jennifer
Members excused:
MANN, Alice, Vice-Chair
BAKER, Dave
A quorum was not present.
Ben Velzen, Assistant Attorney General, Attorney General’s Office and Dr. Stephen Schondelmeyer, Advisory Task Force Member, gave an overview of the Report of the Minnesota Attorney General’s Advisory Task Force on Lowering Pharmaceutical Drug Prices.
A quorum was present at 12:55 P.M.
HF4 Second Engrossment (Lesch) Drug manufacturer or wholesale distributor prohibited from charging unconscionable prices for prescription drugs; Board of Pharmacy, commissioner of human services, and health plan companies required to notify the attorney general of certain prescription drug price increases; attorney general authorized to take action against drug manufacturers and wholesalers related to price increases; civil penalties imposed; and money appropriated.
Chair Liebling moved that HF4 Second Engrossment be recommended to pass and be re-referred to the Committee on Ways and Means.
Representative Lesch presented his bill.
Chair Liebling moved the H0004A4 amendment. THE MOTION PREVAILED AND THE AMENDMENT WAS ADOPTED.
Chair Liebling moved the H0004A5 amendment. THE MOTION PREVAILED AND THE AMENDMENT WAS ADOPTED.
Testifying on HF4:
Ben Velzen, Assistant Attorney General, Attorney General’s Office
Erin Heers-McArdle, TakeAction MN
Judy Cook
Sharon Lamberton, Deputy Vice President, PhRMA
Chair Liebling renewed her motion that HF4 Second Engrossment be recommended to pass as amended and be re-referred to the Committee on Ways and Means. THE MOTION PREVAILED.
HF1246 First Engrossment (Morrison) Prescription Drug Price Transparency Act established, drug manufacturers required to submit drug price information to the commissioner of health, civil penalties provided, and report required.
Chair Liebling moved that HF1246 First Engrossment be recommended to pass and be re-referred to the Committee on Ways and Means.
Chair Liebling moved the H1246DE3 amendment. THE MOTION PREVAILED AND THE AMENDMENT WAS ADOPTED.
Representative Morrison presented her bill.
Testifying on HF1246:
Sharon Lamberton, Deputy Vice President, PhRMA
Chair Liebling renewed her motion that HF1246 First Engrossment be recommended to pass, as amended, and be re-referred to the Committee on Ways and Means. THE MOTION PREVAILED.
HF1257 (Cantrell) Prescription drug benefit transparency and disclosure required.
Representative Cantrell moved that HF1257 be recommended to pass and be re-referred to the Committee on Ways and Means.
Representative Cantrell then moved the H1257DE1 amendment. THE MOTION PREVAILED AND THE AMENDMENT WAS ADOPTED.
Representative Cantrell presented his bill.
Representative Mason gave a brief overview of her bill HF288 to explain the similarities and differences to HF1257.
Testifying on HF1257:
Dr. Renee Crichlow, President, MN Academy of Family Physicians
Sue Abderholden, Executive Director, NAMI-MN
Dan Endreson, Director of Government Affairs and Policy, MN Council of Health Plans
Representative Cantrell renewed his motion that HF1257 be recommended to pass, as amended, and be re-referred to the Committee on Ways and Means. THE MOTION PREVAILED.
The meeting was adjourned at 2:14 P.M.
________________________________________________________
Representative Tina Liebling, Chair
________________________________________________________
Krysta Niedernhöfer, Committee Legislative Assistant